

CURRICULUM VITAE ET STUDIORUM

DR. GIROLAMA ALESSANDRA MARFIA

FAMILY NAME: Marfia

GIVEN NAME: Girolama Alessandra

PLACE and DATE of BIRTH : Melito Porto Salvo (RC), April 15th, 1969

ADDRESS: AOU Policlinico Tor Vergata - Viale Oxford 81 – Roma – Italy - 00133 Tel: +39-06-20903384; Fax: +39-06-20904592; E-mail: marfia@uniroma2.it

Medical license: 45438

PRESENT ACADEMIC POSITION:

1999-present: Assistant Professor of Neurology, Department of Systems Medicine, University of Rome “Tor Vergata”, Via Montpellier 1, 00133 Rome, Italy

PRESENT CLINICAL POSITIONS:

1. Head of the UOSD “Multiple Sclerosis Clinical and Research Center”, Fondazione PTV “Policlinico Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
2. Head of the Regional Reference Center “Immuno-mediated Neuropathies”, Fondazione PTV “Policlinico Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy

EDUCATION:

1993: Degree in Medicine cum laude, University of Rome “Tor Vergata”

1997: Residency in Neurology cum laude, University of Rome “Tor Vergata”

1998-1999: Research Fellow, Cellular Neurobiology Dept., Pierre et Marie Curie University, Paris, France

PRESENT CLINICAL RESEARCH ACTIVITY:

1. Investigate the relationship between the immunological changes due to Multiple Sclerosis (MS) and its treatments and viral infection (i.e. JCV infection)/response to vaccines, aiming to find new biomarkers suitable for risk minimization.
2. Description of clinical outcomes, safety of disease modifying treatments and immunologic dynamics in relation to fertility and pregnancy in MS, particularly focusing on the role of B cells subsets in conditioning the peripartum inflammatory activity, in order to develop new management approaches.
3. Estimate the efficacy and safety of first and second line treatments for MS in the post-marketing setting and of the clinical variables associated with treatment response.
4. Investigate the role of clinical and immunological biomarkers (soluble inflammatory molecules and specific sub-populations of circulating immune cells) in predicting the clinical course of demyelinating disorders of peripheral nervous system and in conditioning the response to standard and innovative treatments.

PAST RESEARCH ACTIVITY:

2002-2012: clinical characterization and therapeutic management of Diabetic Neuropathies; role of autonomic dysfunction in neuromuscular diseases and parkinsonism; diagnostic and therapeutic management of neuropathic pain.

1997-2002: electrophysiological characterization of excitatory and inhibitory synaptic transmission in experimental models of Parkinson’s disease, Huntington’s disease and brain ischemia; receptor and

post-receptor events involved in the modulation of corticostriatal transmission and synaptic plasticity (long-term potentiation and long-term depression).

1993-1996: neuropsychological characterization of cognitive profiles in cortical and subcortical dementia; characterization of implicit and explicit memory deficits in head traumatism.

Since 2016: Principal Investigator of many phase II, III and IV national and international trials with new therapeutic agents for Multiple Sclerosis conducted according to GCP (GCP training 01-Mar-2019)

SPONSOR BIOGEN IDEC

215MS201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex;

DACLIZUMAB 205MS303: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301 ;

HI-TEC(h) BIIT0315: Phase IV, observational, multicenter, comparator arm, 48 weeks study to assess the longitudinal improvement on sleep quality in RRMS patients treated with tecfidera ;

PLATINUM: Studio multicentrico interventistico di fase IV per la valutazione dell'effetto di Plegridy (penna preimpita) sulla soddisfazione in pazienti con Sclerosi Multipla recidivante-remittente insoddisfatti del trattamento con altri DMT iniettabili sottocute ;

POP: Plegridy™ (peginterferon β 1a) Real World Effectiveness and Safety Observational Program (POP) ;

STARTEC: Studio di fase IIb, multicentrico, per la valutazione delle funzioni cognitive in pazienti affetti da SMRR trattati con BG-12.

OCEAN: A multicenter, double-blind, placebo-controlled, parallel-group, dose ranging Phase 2 study to evaluate the efficacy and safety of oral BIIB061 as add-on therapy to interferon-beta1

SARANTA: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrevus), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis" therapies in relapsing multiple sclerosis

SPONSOR GENZYME

SWITCH: indagine trasversale sulla occorrenza e sui fattori clinici che determinano la modifica della terapia in pazienti con SM-RR ;

LEMqoL OBS14449: A prospective observational study to evaluate quality of life, patient-reported outcomes, and safety in patients with RR-MS who are being treated with alemtuzumab (Lemtrada) in routine clinical practice .

NEDA3PLUS: Prospective, Non-interventional, Multicenter, National Study in order to Evaluate the Predictability of NEDA and NEDA3PLUS on the Disability Response over a 96-week Period in Patients Suffering from Relapsing Remitting Multiple Sclerosis treated with Teriflunomide in a Real World Setting

SPONSOR MERCK SERONO

Premiere Registry: Registro prospettico osservazionale sulla sicurezza a lungo termine di pazienti affetti da sclerosi multipla che hanno preso parte agli studi clinici sulla cladribina ;

RELIF: Multicenter, open-label, 12 weeks, phase IV prospective randomized study aimed at evaluating whether sc IFN beta 1a (Rebif®) administered in the morning may affect the severity of Flu-like syndrome and patient-perceived invisible symptoms in subjects with relapsing multiple sclerosis;

INCREASE: Evaluation of clinical recovery after relapse: a pilot study assessing the neuronal effects of D-Aspartate in RR-MS subjects treated with interferon beta 1a 44 mcg TIW

CLASSIC-MS: Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and Oracle study

CLARIFY: A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®

EVOBRUTINIB: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.

SPONSOR ROCHE

CASTING MA3005: Multicenter, Open Label and safety study of Ocrelizumab in RRMS patients sub-optimally controlled with DMTs ;

OPERA 21093: A randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif) in patients with relapsing Multiple Sclerosis ;

ENSAMBLE MA30143: An open label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis

CONSONANCE: An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis

LIBERTO: A single arm, open label multicentre extension study to evaluate the effectiveness and safety of ocrelizumab in patients with multiple sclerosis previously enrolled in a f. hoffmann-la roche sponsored ocrelizumab phase iiib/iv clinical trial

MUSICALE: A multicentre Non interventional study to assess the real world effectiveness of Ocrelizumab in patients with RRMS or PPMS

MS40404 : A phase iiib multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis

FENEBRUTINIB: A PHASE III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary progressive multiple sclerosis

SPONSOR NOVARTIS

CBAF312A2201-EXT: A phase II, double-blind, randomized, multicenter, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with RRMS;

CFTY720D2304: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis ;

CFTY720D2311 : A two-year, Double-blind, Randomized, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis;

CFTY720D2399: Studio multicentrico in aperto a un solo gruppo di trattamento per valutare la sicurezza e la tollerabilità a lungo termine di 0.5 mg di fingolimod somministrato per via orale una volta al giorno in pazienti affetti da Sclerosi Multipla Recidivante-Remittente ;

CFTY720D2405: Studio osservazionale della durata di due anni per valutare il profilo di sicurezza di fingolimod in pazienti con sclerosi multipla che passano dal trattamento con natalizumab al trattamento con fingolimod ;

CFTY720D2406: Studio prospettico, non interventistico, internazionale, a coorti parallele, per valutare la sicurezza a lungo termine in pazienti con sclerosi multipla che hanno recentemente iniziato il trattamento con fingolimod o in terapia con altri farmaci approvati per il trattamento della sclerosi multipla ;

COMB157G2302: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis

SPONSOR TEVA

ARPEGGIO: Studio multinazionale, multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, controllato con placebo per valutare l'efficacia, la sicurezza e la tollerabilità della somministrazione per via orale una volta al giorno di Laquinimod (0,6 o 1,5 mg) in pazienti affetti da sclerosi multipla primaria progressiva (SMPP);

MS-LAQ-301-E1 (ALLEGRO) : studio internazionale, multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, versus placebo, atto a valutare la sicurezza, la tollerabilità e l'efficacia di LAQUINIMOD 0,6 mg, somministrato una volta al giorno per via orale, in pazienti affetti da Sclerosi Multipla recidivante-remittente ;

MS-LAQ-302-E1 (BRAVO): studio internazionale, multicentrico, randomizzato, in doppio cieco, a gruppi paralleli, versus placebo e versus interferone β -1a (Avonex), atto a valutare la sicurezza, la tollerabilità e l'efficacia di LAQUINIMOD 0,6 mg, somministrato una volta al giorno per via orale, in pazienti affetti da Sclerosi Multipla recidivante-remittente ;

PRIMULA: Studio sul valore predittivo di parametri clinici e radiologici dopo un anno di trattamento con Glatimer Acetato (GA), per valutare la successiva attività di malattia in soggetti con CM recidivante-remittente .

OTHER SPONSORS

MT-1303-E05: A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study – SPONSOR MITHSUBISHI;

OPTIMUM: Oral Ponesimod versus Teriflunomide In relapsing Multiple Sclerosis Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis – SPONSOR ACTELION;

REGISTRO ITALIANO SCLEROSI MULTIPLA SM001 e SM002: Studio non interventistico, prospettico di raccolta dati per via elettronica dei pazienti affetti da sclerosi multipla. Studio multicentrico, osservazionale, no profit – PROMOTORE FISM ;

RPC01-201 IND 109,159: Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients – SPONSOR CELGENE.

RPC01-3001: A Multi-site, open label extension trial of oral RPC 1063 in Relapsing Multiple Sclerosis - CHUGAI CELGENE.

ALXN1210-NMO-307: A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) SPONSOR Alexion Pharmaceuticals, Inc.

PUBLICATIONS:

Author of over 100 peer-reviewed papers published in International Journals of Neuroscience and Neurology.

- H-Index: 25 (Source: Scopus)
- Scopus Author ID: 6602742702

- 1) Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini S, Grimaldi A, Landi D, Nicoletti CG, Zingaropoli MA, Iannetta M, Altieri M, Conte A, Limongi D, **Marfia GA**, Ciardi MR, Mastroianni CM, Palamara AT, Moens U, Pietropaolo V. "Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment" *J Clin Med.* 2022 Jan 11;11(2):347. doi: 10.3390/jcm11020347.PMID: 35054041
- 2) Liberatore G, De Lorenzo A, Giannotta C, Manganelli F, Filosto M, Cosentino G, Cocito D, Briani C, Cortese A, Fazio R, Lauria G, Clerici AM, Rosso T, **Marfia GA**, Antonini G, Cavaletti G, Carpo M, Doneddu PE, Spina E, Cotti Piccinelli S, Peci E, Querol L, Nobile-Orazio E. "Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database!" *Neurol Sci.* 2022 Jan 20. doi: 10.1007/s10072-021-05811-0. Online ahead of print. PMID: 35048233
- 3) Belvisi D, Canevelli M, **Marfia GA**, Ferraro E, Centonze D, Salvetti M, Conte A "Response to "Frailty in multiple sclerosis: A closer look at the deficit accumulation framework" *Mult Scler.* 2022 Jan 8:13524585211068150. doi: 10.1177/13524585211068150. Online ahead of print.PMID: 35000469

- 4) Alex Y Doets 1, Hester F Lingsma 2, Christa Walgaard 1 3, Badrul Islam 4, Nowshin Papri 4, Amy Davidson 5, Yuko Yamagishi 6, Susumu Kusunoki 6, Mazen M Dimachkie 7, Waqar Waheed 8, Noah Kolb 8, Zhahirul Islam 4, Quazi Deen Mohammad 9, Thomas Harbo 10, Soren H Sindrup 11, Govindsinh Chavada 5, Hugh J Willison 5, Carlos Casanovas 12, Kathleen Bateman 13, James Al Miller 14, Bianca van den Berg 1 15, Christine Verboon 1, Joyce Roodbol 1, Sonja E Leonhard 1, Luana Benedetti 16, Satoshi Kuwabara 17, Peter Van den Bergh 18, Soledad Monges 19, Girolama **A Marfia** 20, Nortina Shahrizaila 21, Giuliana Galassi 22, Yann Quéron 23, Jan Bürmann 24, Krista Kuitwaard 1 25, Ruud P Kleyweg 25, Cintia Marchesoni 26, María J Sedano Tous 27, Luis Peral 28, Isabel Illa 28, Yuzhong Wang 29, Eduardo Nobile-Orazio 30, Simon Rinaldi 31, Angelo Schenone 32, Julio Pardo 33, Frederique H Vermeij 34, Helmar C Lehmann 35, Volkan Granit 36, Guido Cavaletti 37, Gerardo Gutiérrez-Gutiérrez 38, Fabio A Barroso 39, Leo H Visser 40, Hans D Katzberg 41, Efthimios Dardiotis 42, Shahram Attarian 43, Anneke J van der Kooij 44, Filip Eftimov 44, Paul W Wirtz 45, Johnny Pa Samijn 3, H Jacobus Gilhuis 46, Robert Dm Hadden 47, James KI Holt 48, Kazim A Sheikh 49, Summer Karafiath 50, Michal Vytopil 51, Giovanni Antonini 52, Thomas E Feasby 53, Catharina G Faber 54, Cees J Gijssbers 15, Mark Busby 55, Rhys C Roberts 56, Nicholas J Silvestri 57, Raffaella Fazio 58, Gert W van Dijk 59, Marcel Pj Garssen 60, Chiara Sm Straathof 61, Kenneth C Gorson 62, Bart C Jacobs, IGOS Consortium "Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score" *Neurology*. 2021 Dec 22;10.1212/WNL.0000000000013139. doi: 10.1212/WNL.0000000000013139. Online ahead of print. PMID: 34937789
- 5) Prezioso C, Grimaldi A, Landi D, Nicoletti CG, Brazzini G, Piacentini F, Passerini S, Limongi D, Ciotti M, Palamara AT, **Marfia GA**, Pietropaolo V. "Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment" -Viruses. 2021 Aug 25;13(9):1684. doi: 10.3390/v13091684.
- 6) Iannetta M, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, Buccisano F, Grelli S, Coppola L, Campogiani L, Andreoni M, **Marfia GA**, Sarmati L. "T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers" -Mult Scler Relat Disord. 2021 Jul 21;55:103157. doi: 10.1016/j.msard.2021.103157. Online ahead of print.
- 7) Abbadessa G, Miele G, Cavalla P, Valentino P, **Marfia GA**, Signoriello E, Landi D, Bosa C, Vercellino M, De Martino A, Missione R, Sparaco M, Lavorgna L, Lus G, Bonavita S. "CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab" *Int J Environ Res Public Health*. 2021 Aug 2;18(15):8163. doi: 10.3390/ijerph18158163
- 8) Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M; Italian MS Register "Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration" *J Neurol* 2021 Jul 22. doi: 10.1007/s00415-021-10708-1. Online ahead of print
- 9) Doriana Landi 1 2, Marta Ponzano 3, Carolina Gabri Nicoletti 4 5, Gaia Cola 4 5, Gianluca Cecchi 4 5, Alfonso Grimaldi 4, Giorgia Mataluni 4, Nicola Biagio Mercuri 4 5, Maria Pia Sormani 3, Guglielmo Pacileo 6, Girolama Alessandra Marfia "Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey" *Neurol Sci* 2021 Jul 20;1-9. doi: 10.1007/s10072-021-05398-6. Online ahead of print.
- 10) Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, **Marfia GA**, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group. "PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study" *J Neurol*. 2021 Jun 28. doi: 10.1007/s00415-021-10676-6 Online ahead of print. PMID: 34181077
- 11) Spina E, Doneddu PE, Liberatore G, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Antonini G, Cosentino G, Jann S, Mazzeo A, Cortese A, **Marfia GA**, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Peci E, Tronci S, Ruiz M, Piccinelli SC, Schenone A, Leonardi L, Gentile L, Piccolo L, Mataluni G, Santoro L, Nobile-Orazio E, Manganelli F; Italian CIDP Database Study Group "Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP" *J Neurol*. 2021 Jun 26. doi : 10.1007/s00415-021-10672-w . Online ahead of print. PMID: 34173874
- 12) Landi D, Signori A, Cellerino M, Fenu G, Nicoletti CG, Ponzano M, Mancuso E, Fronza M, Ricchiuto ME, Boffa G, Inglese M, **Marfia GA**, Cocco E, Frau J. "What happens after fingolimod discontinuation? A multicentre real-life experience" *J Neurol*. 2021 Jun 16. doi: 10.1007/s00415-021-10658-8. Online ahead of print. PMID: 34136943
- 13) Barbano L, Ziccardi L, Landi D, Nicoletti CG, Mataluni G, Falsini B, Centonze D, **Marfia GA**, Quaranta L, Parisi V. "Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod" *Adv Ther*. 2021 Jun 9. doi: 10.1007/s12325-021-01728-4. Online ahead of print. PMID: 34109558
- 14) Spina E, Doneddu PE, Liberatore G, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Antonini G, Cosentino G, Jann S, Mazzeo A, Cortese A, **Marfia GA**, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Peci E, Tronci S, Ruiz M, Piccinelli SC, Schenone A, Leonardi L, Gentile L, Piccolo L, Mataluni G, Santoro L, Nobile-Orazio E, Manganelli F; "The neurophysiological lesson from the Italian CIDP database". on the behalf of the Italian CIDP Database Study Group. *Neurol Sci*. 2021 May 21. doi: 10.1007/s10072-021-05321-z. Online ahead PMID: 34021439
- 15) Signoriello E, Lus G, Bonavita S, Lanzillo R, Saccà F, Landi D, Frau J, Baroncini D, Zaffaroni M, Maniscalco GT, Curti E, Sartori A, Cepparulo S, Marfia GA, Nicoletti CG, Carotenuto A, Nociti V, Caleri F, Sormani MP, Signori A. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy *Mult Scler*. 2021 Apr 15:13524585211005657. doi: 10.1177/13524585211005657. Online ahead of print. PMID: 33855897
- 16) Migliore S, Landi D, Proietti F, D'Aurizio G, Squitieri F, Mataluni G, Nicoletti CG, Curcio G, Marfia GA. Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire *Neurol Sci*. 2021 Mar 11. doi: 10.1007/s10072-021-05168-4.. PMID: 33704600
- 17) Migliore S, Landi D, Proietti F, D'Aurizio G, Squitieri F, Mataluni G, Nicoletti CG, Curcio G, **Marfia GA** Validity of the Italian multiple sclerosis neuropsychological screening questionnaire. *Neurol Sci*. 2021 Mar 2. doi: 10.1007/s10072-021-05141-1. Online ahead of print. PMID: 33651198

- 18) Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, Bianchi A, Borriello G, Buscarinu MC, Callari G, Capobianco M, Capone F, Cavalla P, Cavarretta R, Cortese A, De Luca G, Di Filippo M, Dattola V, Fantozzi R, Ferraro E, Filippi MM, Gasperini C, Grimaldi LME, Landi D, Re ML, Mallucci G, Manganotti P, **Marfia GA**, Mirabella M, Perini P, Pisa M, Realmuto S, Russo M, Tomassini V, Torri-Clerici VLA, Zaffaroni M, Zuliani C, Zywicki S, Filippi M, Prosperini L. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. *J Neurol*. 2021 Feb 22;. doi: 10.1007/s00415-021-10455-3. [Epub ahead of print] PubMed PMID: 33616742.
- 19) Belvisi D, Canevelli M, Baione V, Buscarinu MC, Pellicciari G, Fantozzi R, Creta A, Cecchi G, Cola G, Nicoletti CG, Cortese A, De Giglio L, Tartaglia M, Crisafulli SG, Bruno G, Ferraro E, **Marfia GA**, Centonze D, Salvetti M, Conte A. Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation. *Mult Scler*. 2021 Feb 10;:1352458520987541. doi: 10.1177/1352458520987541. [Epub ahead of print] PubMed PMID: 33565913.
- 20) Liberatore G, Manganelli F, Doneddu PE, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Mazzeo A, Antonini G, Cosentino G, Jann S, Cortese A, **Marfia GA**, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Santoro L, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Schenone A, Leonardi L, Toscano A, Mataluni G, Spina E, Gentile L, Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. *Eur J Neurol*. 2021 Feb;28(2):620-629. doi: 10.1111/ene.14545. Epub 2020 Oct 15. PubMed PMID: 32959475.
- 21) Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *Eur J Neurol*. 2021 Feb;28(2):567-578. doi: 10.1111/ene.14589. Epub 2020 Nov 6. PubMed PMID: 33058344.
- 22) Lucchini M, Prosperini L, Buscarinu MC, Centonze D, Conte A, Cortese A, Elia G, Fantozzi R, Ferraro E, Gasperini C, Ianniello A, Landi D, **Marfia GA**, Nociti V, Pozzilli C, Salvetti M, Tortorella C, Mirabella M. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. *J Neurol*. 2021 Jan 26;. doi: 10.1007/s00415-021-10412-0. [Epub ahead of print] PubMed PMID: 33496861.
- 23) Stampanoni Bassi M, Drulovic J, Pekmezovic T, Iezzi E, Sica F, Gilio L, Gentile A, Musella A, Mandolesi G, Furlan R, Finardi A, **Marfia GA**, Bellantonio P, Fantozzi R, Centonze D, Buttari F. Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. *Ther Adv Neurol Disord*. 2020;13:1756286420970833. doi: 10.1177/1756286420970833. eCollection 2020. PubMed PMID: 33343708; PubMed Central PMCID: PMC7727083.
- 24) Ziccardi L, Barbano L, Boffa L, Albanese M, Nicoletti CG, Landi D, Grzybowski A, Falsini B, **Marfia GA**, Centonze D, Parisi V. Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis. *J Clin Med*. 2020 Nov 22;9(11). doi: 10.3390/jcm9113766. PubMed PMID: 33266435; PubMed Central PMCID: PMC7700336.
- 25) Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, Benedetti L, Bianchi E, Jann S, Mazzeo A, Antonini G, Cosentino G, **Marfia GA**, Cortese A, Clerici AM, Carpo M, Schenone A, Siciliano G, Luigetti M, Lauria G, Rosso T, Cavaletti G, Beghi E, Liberatore G, Santoro L, Spina E, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Verrengia EP, Gentile L, Leonardi L, Mataluni G, Piccolo L, Nobile-Orazio E. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. *J Neurol Neurosurg Psychiatry*. 2020 Oct;91(10):1092-1099. doi: 10.1136/jnnp-2020-323615. Epub 2020 Aug 31. PubMed PMID: 32868387.
- 26) Iannetta M, Cesta N, Stingone C, Malagnino V, Teti E, Vitale P, De Simone G, Rossi B, Ansaldo L, Compagno M, Spalliera I, Di Lorenzo A, Landi D, Nicoletti CG, **Marfia GA**, Andreoni M, Sarmati L. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab. *Mult Scler Relat Disord*. 2020 Oct;45:102442. doi: 10.1016/j.msard.2020.102442. Epub 2020 Aug 4. PubMed PMID: 32777745; PubMed Central PMCID: PMC7399651.
- 27) Landi D, Ponzano M, Nicoletti CG, Cecchi G, Cola G, Mataluni G, Mercuri NB, Sormani MP, **Marfia GA**. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. *Mult Scler Relat Disord*. 2020 Oct;45:102359. doi: 10.1016/j.msard.2020.102359. Epub 2020 Jul 3. PubMed PMID: 32663793; PubMed Central PMCID: PMC7333605.
- 28) Stampanoni Bassi M, Buttari F, Simonelli I, Gilio L, Furlan R, Finardi A, **Marfia GA**, Visconti A, Paolillo A, Storto M, Gambardella S, Ferese R, Salvetti M, Uccelli A, Matarese G, Centonze D, De Vito F. A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. *Genes (Basel)*. 2020 Sep 30;11(10). doi: 10.3390/genes11101152. PubMed PMID: 33007809; PubMed Central PMCID: PMC7601054.
- 29) Stampanoni Bassi M, Buttari F, Nicoletti CG, Mori F, Gilio L, Simonelli I, De Paolis N, **Marfia GA**, Furlan R, Finardi A, Centonze D, Iezzi E. Interleukin-1 β Alters Hebbian Synaptic Plasticity in Multiple Sclerosis. *Int J Mol Sci*. 2020 Sep 23;21(19). doi: 10.3390/ijms21196982. PubMed PMID: 32977401; PubMed Central PMCID: PMC7584038.
- 30) Liberatore G, Manganelli F, Doneddu PE, Cocito D, Fazio R, Briani C, Filosto M, Benedetti L, Mazzeo A, Antonini G, Cosentino G, Jann S, Cortese A, **Marfia GA**, Clerici AM, Siciliano G, Carpo M, Luigetti M, Lauria G, Rosso T, Cavaletti G, Santoro L, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Schenone A, Leonardi L, Toscano A, Mataluni G, Spina E, Gentile L, Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. *Eur J Neurol*. 2020 Sep 21;. doi: 10.1111/ene.14545. [Epub ahead of print] PubMed PMID: 32959475.
- 31) Liberatore G, Giannotta C, Sajeev BP, Morengi E, Terenghi F, Gallia F, Doneddu PE, Manganelli F, Cocito D, Filosto M, Antonini G, Cosentino G, **Marfia GA**, Clerici AM, Lauria G, Rosso T, Cavaletti G, Nobile-Orazio E. Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. *J Neuroimmunol*. 2020 Jun 8;345:577288. doi: 10.1016/j.jneuroim.2020.577288. [Epub ahead of print] PubMed PMID: 32544754.
- 32) Di Giuliano F, Minosse S, Picchi E, Marfia GA, Da Ros V, Muto M, Muto M, Pistolesse CA, Laghi A, Garaci F, Floris R. Comparison between synthetic and conventional magnetic resonance imaging in patients with multiple sclerosis and controls. *MAGMA*. 2020 Aug;33(4):549-557. doi: 10.1007/s10334-019-00804-9. Epub 2019 Nov 28. PubMed PMID: 31782035.
- 33) Landi D, **Marfia GA**. Exposure to natalizumab during pregnancy and lactation is safe - Yes. *Mult Scler*. 2020 Jun 8;:1352458520915814. doi: 10.1177/1352458520915814. [Epub ahead of print] PubMed PMID: 32508253.
- 34) Jann S, Fazio R, Cocito D, Toscano A, Schenone A, **MARFIA GA**, Antonini G, De Toni Franceschini L, Mazzeo A, Grandis M, Velardo D, Mataluni G, Peci E. High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to

- Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. *Pain Med.* 2020 Jan 6;. doi: 10.1093/pm/pnz331. [Epub ahead of print] PubMed PMID: 31904855.
- 35) Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M, Mazzeo A, Cosentino G, Cortese A, Jann S, Clerici AM, Antonini G, Siciliano G, Luigetti M, **MARFIA GA**, Briani C, Lauria G, Rosso T, Cavaletti G, Carpo M, Benedetti L, Beghi E, Liberatore G, Santoro L, Peci E, Tronci S, Cotti Piccinelli S, Toscano A, Piccolo L, Verrengia EP, Leonardi L, Schirinzi E, Mataluni G, Ruiz M, Dacci P, Nobile-Orazio E. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. *Eur J Neurol.* 2020 Jan;27(1):136-143. doi: 10.1111/ene.14044. Epub 2019 Aug 9. PubMed PMID: 31325350.
 - 36) Cortese A, Lombardi R, Briani C, Callegari I, Benedetti L, Manganelli F, Luigetti M, Ferrari S, Clerici AM, **MARFIA GA**, Rigamonti A, Carpo M, Fazio R, Corbo M, Mazzeo A, Giannini F, Cosentino G, Zardini E, Currò R, Gastaldi M, Vegezzi E, Alfonsi E, Berardinelli A, Kouton L, Manso C, Giannotta C, Doneddu P, Dacci P, Piccolo L, Ruiz M, Salvalaggio A, De Michelis C, Spina E, Topa A, Bisogni G, Romano A, Mariotto S, Mataluni G, Cerri F, Stancanelli C, Sabatelli M, Schenone A, Marchioni E, Lauria G, Nobile-Orazio E, Devaux J, Franciotta D. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. *Neurol Neuroimmunol Neuroinflamm.* 2020 Jan;7(1). doi: 10.1212/NXI.0000000000000639. Print 2020 Jan. PubMed PMID: 31753915.
 - 37) Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, **MARFIA GA**, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. *J Neurol.* 2019 Sep 18;. doi: 10.1007/s00415-019-09531-6. [Epub ahead of print] PubMed PMID: 31535270.
 - 38) Di Giuliano F, Minosse S, Picchi E, **MARFIA GA**, Da Ros V, Muto M, Muto M, Pistolese CA, Laghi A, Garaci F, Floris R. Comparison between synthetic and conventional magnetic resonance imaging in patients with multiple sclerosis and controls. *MAGMA.* 2019 Nov 28;. doi: 10.1007/s10334-019-00804-9. [Epub ahead of print] PubMed PMID: 31782035
 - 39) Nicoletti CG, Landi D, Monteleone F, Mataluni G, Albanese M, Lauretti B, Rocchi C, Simonelli I, Boffa L, Buttari F, Mercuri NB, Centonze D, **MARFIA GA**. Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis. *CNS Drugs.* 2019 Oct 24;. doi: 10.1007/s40263-019-00676-6. [Epub ahead of print] PubMed PMID: 31650471.
 - 40) Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (**SYNERGY**): a randomised, placebo-controlled, phase 2 trial. *Lancet Neurol.* 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. PubMed PMID: 31285147.
 - 41) Stampanoni Bassi M, Iezzi E, Mori F, Simonelli I, Gilio L, Buttari F, Sica F, De Paolis N, Mandolesi G, Musella A, De Vito F, Dolcetti E, Bruno A, Furlan R, Finardi A, **MARFIA GA**, Centonze D, Rizzo FR. Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue Damage Compensation in Multiple Sclerosis. *Neurorehabil Neural Repair.* 2019 Aug 20;:1545968319868713. doi: 10.1177/1545968319868713. [Epub ahead of print] PubMed PMID: 31431121.
 - 42) Grimaldi AE, De Giglio L, Haggiag S, Bianco A, Cortese A, Crisafulli SG, Monteleone F, **MARFIA G**, Prosperini L, Galgani S, Mirabella M, Centonze D, Pozzilli C, Castelli L. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray). *PLoS One.* 2019;14(7):e0219670. doi: 10.1371/journal.pone.0219670. eCollection 2019. PubMed PMID: 31361750; PubMed Central PMCID: PMC6667203.
 - 43) Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M, Mazzeo A, Cosentino G, Cortese A, Jann S, Clerici AM, Antonini G, Siciliano G, Luigetti M, **MARFIA GA**, Briani C, Lauria G, Rosso T, Cavaletti G, Carpo M, Benedetti L, Beghi E, Liberatore G, Santoro L, Peci E, Tronci S, Cotti Piccinelli S, Toscano A, Piccolo L, Verrengia EP, Leonardi L, Schirinzi E, Mataluni G, Ruiz M, Dacci P, Nobile-Orazio E. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. *Eur J Neurol.* 2019 Jul 20;. doi: 10.1111/ene.14044. [Epub ahead of print] PubMed PMID: 31325350.
 - 44) Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC. **Current treatment practice of Guillain-Barré syndrome.** *Neurology.* 2019 Jul 2;93(1):e59-e76. doi: 10.1212/WNL.00000000000007719. Epub 2019 Jun 7. PubMed PMID: 31175208.
 - 45) Gentile A, De Vito F, Fresegna D, Rizzo FR, Bullitta S, Guadalupi L, Vanni V, Buttari F, Stampanoni Bassi M, Leuti A, Chiurchiù V, **MARFIA GA**, Mandolesi G, Centonze D, Musella A. Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons. *Neuropathol Appl Neurobiol.* 2019 May 24;. doi: 10.1111/nan.12569. [Epub ahead of print] PubMed PMID: 31125471.
 - 46) Massa R, Greco G, Testi M, Rastelli E, Terracciano C, Frezza E, Garibaldi M, **MARFIA GA**, Locatelli F, Mercuri NB, Pompeo E, Antonini G, Andreani M. Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity. *J Neurol.* 2019 Apr;266(4):982-989. doi: 10.1007/s00415-019-09225-z. Epub 2019 Feb 11. PubMed PMID: 30741378.
 - 47) Nicoletti CG, Monteleone F, **MARFIA GA**, Usiello A, Buttari F, Centonze D, Mori F. Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis. *Mult Scler.* 2019 Feb 7;:1352458519828294. doi: 10.1177/1352458519828294. [Epub ahead of print] PubMed PMID: 30730244.
 - 48) Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, Benedetti L, Mazzeo A, **MARFIA GA**, Cortese A, Fierro B, Jann S, Beghi E, Clerici AM, Carpo M, Schenone A, Luigetti M, Lauria G, Antonini G, Rosso T, Siciliano G, Cavaletti G, Liberatore G, Santoro L, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Toscano A, Mataluni G, Piccolo L, Cosentino G, Sabatelli M, Nobile-Orazio E. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. *J Neurol Neurosurg Psychiatry.* 2019 Feb;90(2):125-132. doi: 10.1136/jnnp-2018-318714. Epub 2018 Oct 8. PubMed PMID: 30297520.
 - 49) Stampanoni Bassi M, Gentile A, Iezzi E, Zagaglia S, Musella A, Simonelli I, Gilio L, Furlan R, Finardi A, **MARFIA GA**, Guadalupi L, Bullitta S, Mandolesi G, Centonze D, Buttari F. Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis. *Front Neurol.* 2019;10:30. doi: 10.3389/fneur.2019.00030. eCollection 2019. PubMed PMID: 30761069; PubMed Central PMCID: PMC6361812.

- 50) Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, **MARFIA** GA. Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3. PubMed PMID: 29970387.
- 51) Stampanoni Bassi M, Iezzi E, Landi D, Monteleone F, Gilio L, Simonelli I, Musella A, Mandolesi G, De Vito F, Furlan R, Finardi A, **MARFIA** GA, Centonze D, Buttari F. Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. *J Neurol*. 2018 Nov;265(11):2540-2547. doi: 10.1007/s00415-018-8994-5. Epub 2018 Aug 28. PubMed PMID: 30167879.
- 52) Picconi F, Mataluni G, Ziccardi L, Parravano M, Di Renzo A, Ylli D, Pasqualetti P, Studer V, Chioma L, **MARFIA** GA, Frontoni S. Association between Early Neuroretinal Dysfunction and Peripheral Motor Unit Loss in Patients with Type 1 Diabetes Mellitus. *J Diabetes Res*. 2018;2018:9763507. doi: 10.1155/2018/9763507. eCollection 2018. PubMed PMID: 30402503; PubMed Central PMCID: PMC6193343.
- 53) Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, **MARFIA** GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C. Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study. *CNS Drugs*. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3. PubMed PMID: 30022464.
- 54) Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrzaila N, Sindrup SH, Waqar W, Jacobs BC, IGOS Consortium (**MARFIA** GA Contributor). Regional variation of Guillain-Barré syndrome. *Brain*. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232. PubMed PMID: 30247567.
- 55) Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J, PARADIGMS Study Group (**MARFIA** GA Contributor). Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. *N Engl J Med*. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149. PubMed PMID: 30207920.
- 56) Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, **MARFIA** GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study. *Neurology*. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6. PubMed PMID: 29875218.
- 57) Landi D, Centonze D, **MARFIA** GA, Capra R, Scarpazza C. Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.". *J Clin Apher*. 2018 Jun;33(3):450-451. doi: 10.1002/jca.21616. Epub 2018 Feb 12. PubMed PMID: 29430694.
- 58) Stampanoni Bassi M, Iezzi E, **MARFIA** GA, Simonelli I, Musella A, Mandolesi G, Fresegna D, Pasqualetti P, Furlan R, Finardi A, Mataluni G, Landi D, Gilio L, Centonze D, Buttari F. Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis. *J Neuroinflammation*. 2018 Apr 14;15(1):108. doi: 10.1186/s12974-018-1150-4. PubMed PMID: 29655371; PubMed Central PMCID: PMC5899838.
- 59) Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F, EXPAND Clinical Investigators (**MARFIA** GA Contributor). Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *Lancet*. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. PubMed PMID: 29576505.
- 60) Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, **MARFIA** GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E. The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis. *Neuroepidemiology*. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2. PubMed PMID: 29502114.
- 61) Di Giuliano F, Albanese M, Picchi E, Mori F, Buttari F, **MARFIA** GA, Garaci F, Mercuri NB, Floris R, Centonze D, Marziali S. Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. *Radiol Med*. 2018 Mar;123(3):202-208. doi: 10.1007/s11547-017-0829-4. Epub 2017 Nov 7. PubMed PMID: 29116601.
- 62) Di Caprera E, De Corato L, Giuricin V, Pensabene MC, **MARFIA** G, Melis M, Garaci F, Floris R. Cerebral venous thrombosis presenting like a subdural hemorrhage at magnetic resonance imaging: An Italian case report. *Eur J Radiol Open*. 2018;5:31-34. doi: 10.1016/j.ejro.2017.12.001. eCollection 2018. PubMed PMID: 29719855; PubMed Central PMCID: PMC5926852.
- 63) Signoriello E, Landi D, Monteleone F, Saccà F, Nicoletti CG, Buttari F, Sica F, **MARFIA** GA, Di Iorio G, Lus G, Centonze D. Fingolimod reduces the clinical expression of active demyelinating lesions in MS. *Mult Scler Relat Disord*. 2018 Feb;20:215-219. doi: 10.1016/j.msard.2018.02.002. Epub 2018 Feb 5. PubMed PMID: 29433094.
- 64) Izzi F, Placidi F, Liguori C, Lauretti B, **MARFIA** GA, Pisani A, Mercuri NB, Rocchi C. Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea?. *Sleep Med*. 2018 Feb;42:68-72. doi: 10.1016/j.sleep.2017.09.029. Epub 2017 Oct 23. PubMed PMID: 29458748.
- 65) Monteleone F, Nicoletti CG, Stampanoni Bassi M, Iezzi E, Buttari F, Furlan R, Finardi A, **MARFIA** GA, Centonze D, Mori F. Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain. *J Neuroimmunol*. 2018 Jan 15;314:89-93. doi: 10.1016/j.jneuroim.2017.11.012. Epub 2017 Nov 20. PubMed PMID: 29174194.
- 66) Stampanoni Bassi M, Gilio L, Buttari F, Maffei P, **MARFIA** GA, Restivo DA, Centonze D, Iezzi E. Remodeling Functional Connectivity in Multiple Sclerosis: A Challenging Therapeutic Approach. *Front Neurosci*. 2017;11:710. doi: 10.3389/fnins.2017.00710. eCollection 2017. Review. PubMed PMID: 29321723; PubMed Central PMCID: PMC5733539.

- 67) Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M, Golden Study Group (**MARFIA** GA Contributor). Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). *J Neurol*. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23. PubMed PMID: 29063244; PubMed Central PMCID: PMC5688215.
- 68) Campagnolo M, Zambello R, Nobile-Orazio E, Benedetti L, **MARFIA** GA, Riva N, Castellani F, Bianco M, Salvalaggio A, Garnero M, Ruiz M, Mataluni G, Fazio R, Ermani M, Briani C. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. *J Neurol Neurosurg Psychiatry*. 2017 Dec;88(12):1094-1097. doi: 10.1136/jnnp-2017-315736. Epub 2017 May 13. PubMed PMID: 28501820.
- 69) Stampanoni Bassi M, Garofalo S, **MARFIA** GA, Gilio L, Simonelli I, Finardi A, Furlan R, Sancesario GM, Di Giandomenico J, Storto M, Mori F, Centonze D, Iezzi E. Amyloid- β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis. *Front Mol Neurosci*. 2017;10:390. doi: 10.3389/fnmol.2017.00390. eCollection 2017. PubMed PMID: 29209169; PubMed Central PMCID: PMC5702294.
- 70) Boso F, Ruggiero S, Giannotta C, Benedetti L, **MARFIA** GA, Ermani M, Campagnolo M, Salvalaggio A, Gallia F, De Michelis C, Visentin A, Bianco M, Ruiz M, Mataluni G, Nobile-Orazio E, Briani C. Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies. *Eur J Neurol*. 2017 Nov;24(11):1334-1340. doi: 10.1111/ene.13387. Epub 2017 Aug 7. PubMed PMID: 28782863.
- 71) Stampanoni Bassi M, Mori F, Buttari F, **MARFIA** GA, Sancesario A, Centonze D, Iezzi E. Neurophysiology of synaptic functioning in multiple sclerosis. *Clin Neurophysiol*. 2017 Jul;128(7):1148-1157. doi: 10.1016/j.clinph.2017.04.006. Epub 2017 Apr 24. Review. PubMed PMID: 2851127.
- 72) Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ, IGOS Consortium (**MARFIA** GA Contributor). International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. *J Peripher Nerv Syst*. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209. PubMed PMID: 28406555.
- 73) Buttari F, Zagaglia S, Marciano L, Albanese M, Landi D, Nicoletti CG, Mercuri NB, Silvestrini M, Provinciali L, **MARFIA** GA, Mori F, Centonze D. TRPV1 polymorphisms and risk of interferon β -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. *J Neuroimmunol*. 2017 Apr 15;305:172-174. doi: 10.1016/j.jneuroim.2017.02.007. Epub 2017 Feb 8. PubMed PMID: 28284340.
- 74) Studer V, Rocchi C, Motta C, Lauretti B, Perugini J, Brambilla L, Pareja-Gutierrez L, Camera G, Barbieri FR, **MARFIA** GA, Centonze D, Rossi S. Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability. *Mult Scler J Exp Transl Clin*. 2017 Apr-Jun;3(2):2055217317701317. doi: 10.1177/2055217317701317. eCollection 2017 Apr-Jun. PubMed PMID: 28607756; PubMed Central PMCID: PMC5408506.
- 75) Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, **MARFIA** GA, Sormani MP, Capra R, Centonze D. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. *Neurology*. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. PubMed PMID: 28228569.
- 76) Marziali S, Picchi E, Di Giuliano F, Altobelli S, Mataluni G, **MARFIA** G, Garaci F, Floris R. Acute disseminated encephalomyelitis following *Campylobacter jejuni* gastroenteritis: Case report and review of the literature. *Neuroradiol J*. 2017 Feb;30(1):65-70. doi: 10.1177/1971400916680123. Epub 2016 Nov 25. Review. PubMed PMID: 27888275; PubMed Central PMCID: PMC5564347.
- 77) D'Amato C, Morganti R, Greco C, Di Gennaro F, Cacciotti L, Longo S, Mataluni G, Lauro D, **MARFIA** GA, Spallone V. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. *Diab Vasc Dis Res*. 2016 Nov;13(6):418-428. doi: 10.1177/1479164116653240. Epub 2016 Jun 22. PubMed PMID: 27334483.
- 78) Mori F, Nisticò R, Nicoletti CG, Zagaglia S, Mandolesi G, Piccinin S, Martino G, Finardi A, Rossini PM, **MARFIA** GA, Furlan R, Centonze D. RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. *Mult Scler*. 2016 Oct;22(11):1405-1412. doi: 10.1177/1352458515621796. Epub 2016 Jan 5. PubMed PMID: 26733422.
- 79) Albanese M, Zagaglia S, Landi D, Boffa L, Nicoletti CG, Marciani MG, Mandolesi G, **MARFIA** GA, Buttari F, Mori F, Centonze D. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. *J Neuroinflammation*. 2016 Feb 10;13:36. doi: 10.1186/s12974-016-0502-1. PubMed PMID: 26863878; PubMed Central PMCID: PMC4750170.
- 80) Imbriani P, **MARFIA** GA, Marciani MG, Poleggi A, Pocchiari M, Puoti G, Caltagirone C, Pisani A. Heidenhain variant in two patients with inherited V210I Creutzfeldt-Jakob disease. *Int J Neurosci*. 2016;126(4):381-3. doi: 10.3109/00207454.2015.1047017. Epub 2015 Aug 13. PubMed PMID: 26268049.
- 81) Mandolesi G, Gentile A, Musella A, Fresegna D, De Vito F, Bullitta S, Sepman H, **MARFIA** GA, Centonze D. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. *Nat Rev Neurol*. 2015 Dec;11(12):711-24. doi: 10.1038/nrneurol.2015.222. Epub 2015 Nov 20. Review. PubMed PMID: 26585978.
- 82) Rocchi C, Albanese M, Placidi F, Romigi A, Lauretti B, **MARFIA** GA, Liguori C, Marciani MG, Mercuri NB, Izzi F. Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. *Sleep Med*. 2015 Sep;16(9):1071-6. doi: 10.1016/j.sleep.2015.04.016. Epub 2015 May 28. PubMed PMID: 26298781.
- 83) Carosi L, Lo Giudice T, Di Lullo M, Lombardi F, Babalini C, Gaudiello F, **MARFIA** GA, Massa R, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: a novel mutation and expansion of the phenotype variability in SPG10. *J Neurol Neurosurg Psychiatry*. 2015 Jun;86(6):702-4. doi: 10.1136/jnnp-2014-308625. Epub 2014 Oct 28. PubMed PMID: 25352184; PubMed Central PMCID: PMC4453490.
- 84) Garaci F, Toschi N, Lanzafame S, **MARFIA** GA, Marziali S, Meschini A, Di Giuliano F, Simonetti G, Guerrisi M, Massa R, Floris R. Brain MR diffusion tensor imaging in Kennedy's disease. *Neuroradiol J*. 2015 Apr;28(2):126-32. doi: 10.1177/1971400915581740. Epub 2015 May 11. PubMed PMID: 25963157; PubMed Central PMCID: PMC4757151.
- 85) Rossi S, Rocchi C, Studer V, Motta C, Lauretti B, Germani G, Macchiarulo G, **MARFIA** GA, Centonze D. The autonomic balance predicts cardiac responses after the first dose of fingolimod. *Mult Scler*. 2015 Feb;21(2):206-16. doi: 10.1177/1352458514538885. Epub 2014 Jun 23. PubMed PMID: 24957049.

- 86) Rossi S, Motta C, Studer V, Rocchi C, Macchiarulo G, Barbieri F, **MARFIA** G, Furlan R, Martino G, Mancino R, Centonze D. Interleukin-8 is associated with acute and persistent dysfunction after optic neuritis. *Mult Scler.* 2014 Dec;20(14):1841-50. doi: 10.1177/1352458514537365. Epub 2014 May 29. PubMed PMID: 24876157.
- 87) Izzi F, Placidi F, Romigi A, Lauretti B, **MARFIA** GA, Mercuri NB, Marcianni MG, Rocchi C. Is autonomic nervous system involved in restless legs syndrome during wakefulness?. *Sleep Med.* 2014 Nov;15(11):1392-7. doi: 10.1016/j.sleep.2014.06.022. Epub 2014 Aug 22. PubMed PMID: 25266501.
- 88) Cocito D, Merola A, Peci E, Mazzeo A, Fazio R, Francia A, Valentino P, Liguori R, Filosto M, Siciliano G, Clerici AM, Lelli S, **MARFIA** GA, Antonini G, Cecconi I, Nobile-Orazio E, Lopiano L. Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. *J Neurol.* 2014 Nov;261(11):2159-64. doi: 10.1007/s00415-014-7444-2. Epub 2014 Aug 23. PubMed PMID: 25149866.
- 89) D'Amato C, Morganti R, Di Gennaro F, Greco C, **MARFIA** GA, Spallone V. A novel association between nondipping and painful diabetic polyneuropathy. *Diabetes Care.* 2014 Sep;37(9):2640-2. doi: 10.2337/dc14-0528. Epub 2014 Jun 26. PubMed PMID: 24969576.
- 90) Ciccacci C, Morganti R, Di Fusco D, D'Amato C, Cacciotti L, Greco C, Rufini S, Novelli G, Sangiuolo F, **MARFIA** GA, Borgiani P, Spallone V. Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes. *Acta Diabetol.* 2014 Aug;51(4):663-71. doi: 10.1007/s00592-014-0582-2. Epub 2014 Mar 30. PubMed PMID: 24682535.
- 91) Bosi E, Bax G, Scionti L, Spallone V, Tesfaye S, Valensi P, Ziegler D, FREMS European Trial Study Group (**MARFIA** GA Contributor). Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. *Diabetologia.* 2013 Mar;56(3):467-75. doi: 10.1007/s00125-012-2795-7. Epub 2012 Dec 13. PubMed PMID: 23238789; PubMed Central PMCID: PMC3563945.
- 92) Testi M, Terracciano C, Guagnano A, Testa G, **MARFIA** GA, Pompeo E, Andreani M, Massa R. Association of HLA-DQB1*05:02 and DRB1*16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis. *Autoimmune Dis.* 2012;2012:541760. doi: 10.1155/2012/541760. Epub 2012 Oct 9. PubMed PMID: 23091703; PubMed Central PMCID: PMC3474207.
- 93) Rocchi C, Pierantozzi M, Pisani V, **MARFIA** GA, Di Giorgio A, Stanzione P, Bernardi G, Stefani A. The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease. *Eur Neurol.* 2012;68(3):187-92. doi: 10.1159/000339000. Epub 2012 Aug 28. PubMed PMID: 22948481.
- 94) Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, **MARFIA** GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med.* 2012 May;29(5):578-85. doi: 10.1111/j.1464-5491.2011.03500.x. PubMed PMID: 22023377.
- 95) Rocchi C, Greco V, Urbani A, Di Giorgio A, Priori M, Massa R, Bernardi G, **MARFIA** GA. Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease). *Muscle Nerve.* 2011 Nov;44(5):737-40. doi: 10.1002/mus.22159. PubMed PMID: 22006688.
- 96) Spallone V, Morganti R, D'Amato C, Cacciotti L, Fedele T, Maiello MR, **MARFIA** G. Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function. *Eur J Pain.* 2011 Feb;15(2):153-60. doi: 10.1016/j.ejpain.2010.06.011. Epub 2010 Jul 8. PubMed PMID: 20619708.
- 97) Terracciano C, Fiore S, Doldo E, Manzari V, **MARFIA** GA, Bernardi G, Massa R, Albonici L. Inverse correlation between VEGF and soluble VEGF receptor 2 in POEMS with AIDP responsive to intravenous immunoglobulin. *Muscle Nerve.* 2010 Sep;42(3):445-8. doi: 10.1002/mus.21718. PubMed PMID: 20589895.
- 98) Aprile I, Tonali P, Caliandro P, Pazzaglia C, Foschini M, Di Stasio E, Mondelli M, Padua L. Italian multicentre study of peroneal mononeuropathy: multiperspective follow-up. *Neurol Sci.* 2009 Feb;30(1):37-44. doi: 10.1007/s10072-009-0010-5. Epub 2009 Jan 20. PubMed PMID: 19153647.
- 99) Finazzi-Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, Sciobica F, **MARFIA** GA. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. *NeuroUrol Urodyn.* 2009;28(4):320-4. doi: 10.1002/nau.20651. PubMed PMID: 19090588.
- 100) Centonze D, Koch G, Versace V, Mori F, Rossi S, Brusa L, Grossi K, Torelli F, Prosperetti C, Cervellino A, **MARFIA** GA, Stanzione P, Marcianni MG, Boffa L, Bernardi G. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. *Neurology.* 2007 Mar 27;68(13):1045-50. doi: 10.1212/01.wnl.0000257818.16952.62. PubMed PMID: 17389310.
- 101) Centonze D, Petta F, Versace V, Rossi S, Torelli F, Prosperetti C, Rossi S, **MARFIA** GA, Bernardi G, Koch G, Miano R, Boffa L, Finazzi-Agrò E. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. *Mult Scler.* 2007 Mar;13(2):269-71. doi: 10.1177/1352458506070729. Epub 2007 Jan 29. PubMed PMID: 17439897.
- 102) Caselli A, Spallone V, **MARFIA** GA, Battista C, Pachatz C, Veves A, Uccioli L. Validation of the nerve axon reflex for the assessment of small nerve fibre dysfunction. *J Neurol Neurosurg Psychiatry.* 2006 Aug;77(8):927-32. doi: 10.1136/jnnp.2005.069609. Epub 2006 Apr 19. PubMed PMID: 16624842; PubMed Central PMCID: PMC2077635.
- 103) **MARFIA** GA, Pachatz C, Terracciano C, Leone G, Bernardini S, Bernardi G, Massa R. Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b. *Neurol Sci.* 2005 Dec;26(5):355-7. doi: 10.1007/s10072-005-0500-z. PubMed PMID: 16388373.
- 104) Koch G, Stefani A, Panella M, Giordano A, Schillaci O, **MARFIA** GA. Posterior cortical atrophy with unilateral occipito-temporal degeneration. *J Neurol.* 2004 Dec;251(12):1530-1. doi: 10.1007/s00415-004-0573-2. PubMed PMID: 15645358.
- 105) **MARFIA** GA, Pachatz C, Arciprete F, Massa R, Gianni G, Iani C. Intestinal pseudobstruction as presenting event of fatal cerivastatin-induced myopathy. *J Neurol.* 2003 Jul;250(7):887-8. doi: 10.1007/s00415-003-1124-y. PubMed PMID: 12883940.
- 106) Calabresi P, Saulle E, Centonze D, Pisani A, **MARFIA** GA, Bernardi G. Post-ischaemic long-term synaptic potentiation in the striatum: a putative mechanism for cell type-specific vulnerability. *Brain.* 2002 Apr;125(Pt 4):844-60. PubMed PMID: 11912117.

- 107) Calabresi P, Saulle E, **MARFIA** GA, Centonze D, Mulloy R, Picconi B, Hipskind RA, Conquet F, Bernardi G. Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. *Mol Pharmacol*. 2001 Oct;60(4):808-15. PubMed PMID: 11562444.
- 108) Calabresi P, Ammassari-Teule M, Gubellini P, Sancesario G, Morello M, Centonze D, **MARFIA** GA, Saulle E, Passino E, Picconi B, Bernardi G. A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication. *Neurobiol Dis*. 2001 Jun;8(3):419-32. doi: 10.1006/nbdi.2000.0379. PubMed PMID: 11442351.
- 109) Centonze D, **MARFIA** GA, Pisani A, Picconi B, Giacomini P, Bernardi G, Calabresi P. Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. *Prog Neurobiol*. 2001 Apr;63(6):687-96. Review. PubMed PMID: 11165001.
- 110) Calabresi P, Centonze D, Gubellini P, **MARFIA** GA, Pisani A, Sancesario G, Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. *Prog Neurobiol*. 2000 Jun;61(3):231-65. Review. PubMed PMID: 10727775.
- 111) Calabresi P, Napolitano M, Centonze D, **MARFIA** GA, Gubellini P, Teule MA, Berretta N, Bernardi G, Frati L, Tolu M, Gulino A. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. *Eur J Neurosci*. 2000 Mar;12(3):1002-12. PubMed PMID: 10762331.
- 112) Calabresi P, Stefani A, **MARFIA** GA, Hainsworth AH, Centonze D, Saulle E, Spadoni F, Leach MJ, Giacomini P, Bernardi G. Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. *Exp Neurol*. 2000 Mar;162(1):171-9. doi: 10.1006/exnr.2000.7285. PubMed PMID: 10716897.
- 113) Napolitano M, **MARFIA** GA, Vacca A, Centonze D, Bellavia D, Di Marcotullio L, Frati L, Bernardi G, Gulino A, Calabresi P. Modulation of gene expression following long-term synaptic depression in the striatum. *Brain Res Mol Brain Res*. 1999 Sep 8;72(1):89-96. PubMed PMID: 10521602.
- 114) Carlesimo GA, Mauri M, **MARFIA** GA, Fadda L, Turriziani P, Caltagirone C. Lexical and conceptual components of stem completion priming in patients with Alzheimer's disease. *Neuropsychologia*. 1999 Aug;37(9):1049-59. PubMed PMID: 10468368.
- 115) Calabresi P, **MARFIA** GA, Amoroso S, Pisani A, Bernardi G. Pharmacological inhibition of the Na(+)/Ca(2+) exchanger enhances depolarizations induced by oxygen/glucose deprivation but not responses to excitatory amino acids in rat striatal neurons. *Stroke*. 1999 Aug;30(8):1687-94. PubMed PMID: 10436122.
- 116) Calabresi P, Centonze D, Gubellini P, **MARFIA** GA, Bernardi G. Glutamate-triggered events inducing corticostriatal long-term depression. *J Neurosci*. 1999 Jul 15;19(14):6102-10. PubMed PMID: 10407046.
- 117) Pisani A, Calabresi P, Centonze D, **MARFIA** GA, Bernardi G. Electrophysiological recordings and calcium measurements in striatal large aspiny interneurons in response to combined O₂/glucose deprivation. *J Neurophysiol*. 1999 May;81(5):2508-16. doi: 10.1152/jn.1999.81.5.2508. PubMed PMID: 10322086.
- 118) Calabresi P, Centonze D, **MARFIA** GA, Pisani A, Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. *Br J Pharmacol*. 1999 Feb;126(3):689-96. doi: 10.1038/sj.bjp.0702361. PubMed PMID: 10188980; PubMed Central PMCID: PMC1565865.
- 119) Calabresi P, **MARFIA** GA, Centonze D, Pisani A, Bernardi G. Sodium influx plays a major role in the membrane depolarization induced by oxygen and glucose deprivation in rat striatal spiny neurons. *Stroke*. 1999 Jan;30(1):171-9. PubMed PMID: 9880406.
- 120) Centonze D, Calabresi P, Pisani A, Marinelli S, **MARFIA** GA, Bernardi G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. *Neuropharmacology*. 1998 Aug;37(8):1063-70. PubMed PMID: 9833635.
- 121) Calabresi P, Centonze D, Pisani A, Sancesario G, Gubellini P, **MARFIA** GA, Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. *Ann Neurol*. 1998 May;43(5):586-97. doi: 10.1002/ana.410430506. PubMed PMID: 9585352.
- 122) Carlesimo GA, **MARFIA** GA, Loasses A, Caltagirone C. Perceptual and conceptual components in implicit and explicit stem completion. *Neuropsychologia*. 1996 Aug;34(8):785-92. PubMed PMID: 8817508.
- 123) Carlesimo GA, **MARFIA** GA, Loasses A, Caltagirone C. Recency effect in anterograde amnesia: evidence for distinct memory stores underlying enhanced retrieval of terminal items in immediate and delayed recall paradigms. *Neuropsychologia*. 1996 Mar;34(3):177-84. PubMed PMID: 8868275.
- 124) Carlesimo GA, Caltagirone C, Gainotti G, Fadda L, Gallassi R, Lorusso S, **MARFIA** GA, Marra C, Nocentini U, Parnetti L. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. *Eur Neurol*. 1996;36(6):378-84. doi: 10.1159/000117297. PubMed PMID: 8954307.
- 125) Carlesimo GA, Fadda L, **MARFIA** GA, Caltagirone C. Explicit memory and repetition priming in dementia: evidence for a common basic mechanism underlying conscious and unconscious retrieval deficits. *J Clin Exp Neuropsychol*. 1995 Feb;17(1):44-57. doi: 10.1080/13803399508406580. PubMed PMID: 7608301.

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

I declare I have read and I am familiar with local clinical trial regulatory requirements (e.g. laws regulations, guidelines) gathered from AIFA website.

Rome, 02/03/2022

